Sentences with phrase «rheumatology annual»

A high percentage of rheumatoid arthritis patients discontinue triple therapy, a combination of disease - modifying antirheumatic drugs, after one to two years, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

Patients with hip and knee osteoarthritis may improve their pain, stiffness and physical function with sustained physical exercise, manual therapy or both, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in Boston.

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

The findings were presented at the American College of Rheumatology annual meeting in San Francisco.

Denosumab (Prolia ®, Xgeva ®) reversed cortical bone loss and increased bone mineral density, lowering wrist fracture rates in women with osteoporosis, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in Boston.

Not exact matches

But Novartis, Celgene, and Pfizer are now duking it in the psoriatic arthritis space, unveiling positive clinical trial data for inflammatory drugs Cosentyx, Otezla, and Xeljanz (respectively) during the American College of Rheumatology's (ACR) annual meeting.

Cosentyx can steadily improve the signs and symptoms of psoriatic arthritis — including patient - reported pain — over three years, Novartis said at the American College of Rheumatology's (ACR) annual meeting.

Yesterday, at the annual American College of Rheumatology meeting in Atlanta, Ga., researchers announced the results of a double - blind, randomized trial in more than 600 patients: tasocitinib eased pain and inflammation in 65.7 percent of those who received the highest dose of the drug, whereas only 26.7 percent of those who received a placebo reported relief.

The study, titled, «The Effectiveness of a Low - Impact Exercise Program on Musculoskeletal Health of Asian Older Adults,» will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals annual meeting on November 9 in San Francisco.

The study was among Mayo Clinic research being presented at the American College of Rheumatology's annual meeting.

The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference confirmed the link between active smoking and the risk of developing rheumatoid arthritis (RA).

The results of two studies presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).

The new study, which was presented this weekend at an annual meeting of the American College of Rheumatology, sought to address that weakness.